Statement from Jamie Bay Nishi, Director, Global Health Technologies Coalition, on the US Food and Drug Administration’s approval of pretomanid, a new drug developed by the nonprofit TB Alliance.
This legislation is an important step forward in strengthening our nation’s preparedness against global disease threats. We applaud the Administration and Congress for recognizing that protecting our nation’s health requires deploying BARDA’s unique capabilities to combat all hazards—not only chemical, biological, radiological and nuclear threats, but naturally occurring health threats as well.
GHTC has opened nominations for its 2019 Innovating for Impact Awards. Now in its third year, this initiative celebrates the partnerships and policymakers driving global health innovation. The nomination deadline is July 31, 2019.
The passage of PAHPAI is an important action by Congress to strengthen our nation’s preparedness against global disease threats. We applaud Congress for recognizing that protecting our nation’s health requires deploying BARDA’s unique capabilities to combat all hazards—not only chemical, biological, radiologic and nuclear threats, but naturally occurring health threats as well.
Next week’s World Health Assembly will be setting priorities that have enormous life-altering implications for billions of people around the world. The Global Health Technologies Coalition (GHTC) is calling on World Health Organization (WHO) member states to increase investments in research and development (R&D), as new tools and technologies are essential for meeting urgent challenges, from achieving universal health coverage (UHC) to fighting antimicrobial resistance (AMR), including drug-resistant tuberculosis (DR-TB), and emerging threats like Ebola.
The United States has long led the world in developing vaccines, drugs, diagnostics, and other technologies for neglected diseases and conditions that affect the world’s most vulnerable people, and the President’s budget proposal threatens to undermine this scientific and humanitarian legacy.
A global coalition of charities, businesses, product development partnerships and academics have come together to say the G20 is failing to meet today’s urgent health challenges and this will only be solved if heads of government and finance ministers take charge to stop this severe threat to the global economy as well as to humanity.
GHTC applauds yesterday's Senate passage of the Global Health Innovation Act, a bipartisan bill to support efforts by the US Agency for International Development to develop affordable, appropriate technologies to advance the health of people in the world’s poorest places. The bill, which has already passed the House of Representatives, now heads to the President’s desk where he is expected to sign it into law.
GHTC yesterday honored Senator Roy Blunt (R-MO) and Congresswoman Rosa DeLauro (D-CT) at its second annual Innovating for Impact Awards, which celebrates US policymakers and partnerships driving progress in global health innovation. GHTC also recognized the partnership that developed and introduced improved child-friendly tuberculosis (TB) medicines, making these transformative treatments available to children in need worldwide.
GHTC has opened nominations for its 2018 Innovating for Impact Awards. Now in its second year, this initiative celebrates the partnerships and policymakers driving global health innovation. The nomination deadline is August 17, 2018.
GHTC welcomes the publication today by the World Health Organization (WHO) of its first Essential Diagnostics List, a critical new tool to help guide governments on the vital diagnostic tests that should be made available through health care systems.
The Trump Administration’s proposal to slash funding to fight global health threats like malaria, Ebola, and HIV/AIDS could cost states thousands of jobs and millions of dollars in economic investment and put the health of residents at risk, according to a new state-by-state analysis released today on Capitol Hill by the Global Health Technologies Coalition.
